Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 11, 2009, Pages 1429-1445

  Bays, Harold E ^a  

^a Louisville Metab Atherosclerosis R   (United States)

Author keywords

Adiposity; Adiposopathy; Diabetes mellitus; Dyslipidemia; High blood pressure; Hypertension; Lorcaserin; Obesity; Sick fat

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMFEBUTAMONE PLUS ZONISAMIDE; ANTIOBESITY AGENT; CANNABINOID RECEPTOR AGONIST; CONTRAVE; DEXFENFLURAMINE; EMPATIC; FATTY ACID; FENFLURAMINE; LEVOFENFLURAMINE; LORCASERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PIOGLITAZONE; PLACEBO; QNEXA; ROSIGLITAZONE; SEROTONIN 2C AGONIST; SEROTONIN AGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

ADIPOGENESIS; ADIPOSE TISSUE; ADIPOSOPATHY; AORTA VALVE REGURGITATION; BARIATRIC SURGERY; CLINICAL TRIAL; DIET THERAPY; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FOOD DRUG INTERACTION; HEART VALVE; HUMAN; IMMUNE RESPONSE; LIPID DIET; LONG TERM CARE; LUNG ARTERY PRESSURE; METABOLIC DISORDER; NAUSEA; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STOMACH BYPASS; VALVULAR HEART DISEASE; WEIGHT REDUCTION; XEROSTOMIA;

ADIPOSITY; ANTI-OBESITY AGENTS; BENZAZEPINES; BODY WEIGHT; HUMANS; METABOLIC DISEASES; OBESITY; RECEPTOR, SEROTONIN, 5-HT2C;

EID: 73349135022     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.123     Document Type: Review

References (121)

1. Kushner RF, Roth JL. Assessment of the obese patient. Endocrinol. Metab. Clin. North Am. 32(4), 915-933 (2003).
2. Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiol. 1(1), 39-59 (2005).
3. Bays HE, Gonzalez-Campoy JM et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev. Cardiovasc. Ther. 6(3), 343-368 (2008). •• Comprehensive review of the pathogenic effects of adipose tissue, with many tables relevant to the potential pathophysiological properties of adipose tissue.
4. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of Type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab. 89(2), 463-478 (2004).
5. Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol. 1(4), 389-420 (2006).
6. Bays HE, Gonzalez-Campoy JM, Henry RR et al. Is adiposopathy (sick fat) an endocrine disease? Int. J. Clin. Pract. 62(10), 1474-1483 (2008). • Consensus paper explaining why 'sick fat' is an endocrine disease.
7. Khan T, Muise ES, Iyengar P et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol. Cell. Biol. 29(6), 1575-1591 (2009).
8. Bays HE, Laferrere B, Dixon J et al. Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease? A consensus from the adiposopathy and bariatric surgery group. Int. J. Clin. Pract. (2009) (In Press). • Consensus paper describing why 'sick fat' is a surgical disease.
9. Bluher M. Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes 117(6), 241-250 (2009). •• Excellent review of the pathogenic potential of adipose tissue.
10. Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev. Cardiovasc. Ther. 3(3), 393-404 (2005).
11. Bays HE. 'Sick fat,' metabolic disease, and atherosclerosis. Am. J. Med. 122(1 Suppl.), S26-S37 (2009). • Provides 'hard-to-find' figures that reflect data regarding the frequency of metabolic disease among a range of BMI, and the range of BMI among those with metabolic disease.
12. Bays H, Blonde L, Rosenson R. Adiposopathy: how do diet, exercise, weight loss and drug therapies improve metabolic disease? Expert Rev. Cardiovasc. Ther. 4(6), 871-895 (2006).
13. Bays HE, Rodbard RW, Schorr AB, González-Campoy JM. Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr. Treat Options Cardiovasc. Med. 9(4), 259-271 (2007).
14. Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int. J. Clin. Pract. 61(5), 737-747 (2007).
15. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J. Am. Coll. Cardiol. 53(21), 1925-1932 (2009).
16. Davenport DL, Xenos ES, Hosokawa P, Radford J, Henderson WG, Endean ED. The influence of body mass index obesity status on vascular surgery 30-day morbidity and mortality. J. Vasc. Surg. 49(1), 140-147, 147 (2009).
17. Orpana HM, Berthelot JM, Kaplan MS, Feeny DH, McFarland B, Ross NA. BMI and mortality: results from a national longitudinal study of canadian adults. Obesity (Silver.Spring) DOI: 10.1038/ oby.2009.191 (2009) (Epub ahead of print).
18. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J. Clin. Endocrinol. Metab. 89(6), 2569-2575 (2004). • Pathogenic potential of adipose tissue is dependent upon where adiposity occurs.
19. Tsai AG, Wadden TA. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann. Intern. Med. 142(1), 56-66 (2005).
20. Rubino F. Is Type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care 31(Suppl. 2), S290-S296 (2008).
21. Patel MR, Donahue M, Wilson PW, Califf RM. Clinical trial issues in weight-loss therapy. Am. Heart J. 151(3), 633-642 (2006).
22. Bays H. Adiposopathy: the endocannabinoid system as a therapeutic treatment target for dysfunctional 'sick' fat. CJHP 19(1), 32-39 (2007).
23. Hausenloy DJ. Contrave TM: novel treatment for obesity. Clin. Lipidol. 4(3), 279-285 (2009).
24. Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J. Clin. Psychiatry 68(8), 1226-1229 (2007).
25. Gadde KM, Yonish GM, Foust MS, Tam PY, Najarian T. A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, in obese adults. Presented at: Program and abstracts of the Annual Scientific Scientific Meeting of NAASO, The Obesity Society, 2006. Boston, MA, USA, 20-24 October 2006.
26. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann. Intern. Med. 143(5), 380-385 (2005) • Entertaining review of the turmoil regarding anti-obesity drug development.
27. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin. Drug Saf. 4(6), 1083-1095 (2005). •• Excellent review of the historic safety aspects of anti-obesity drug development.
28. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 142(7), 525-531 (2005).
29. Varady KA, Tussing L, Bhutani S, Braunschweig CL. Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism 58(8), 1096-1101 (2009).
30. Ratner RE. An update on the Diabetes Prevention Program. Endocr. Pract. 12(Suppl. 1), 20-24 (2006).
31. Nair RP, Ren J. Pharmacotherapy of obesity-benefit, bias and hyperbole. Curr. Med. Chem. 16(15), 1888-1897 (2009).
32. Bays H, Dujovne C. Anti-obesity drug development. Expert Opin. Investig. Drugs 11(9), 1189-1204 (2002).
33. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes. Res. 12(8), 1197-1211 (2004).
34. Magni P, Dozio E, Ruscica M et al. Feeding behavior in mammals including humans. Ann. NY Acad. Sci. 1163, 221-232 (2009).
35. Lenard NR, Berthoud HR. Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity (Silver.Spring) 16)Suppl. 3) S11-S22 (2008).
36. Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J. Physiol. 587(Pt 1), 49-60 (2009).
37. Akana SF. Feeding and stress interact through the serotonin 2C receptor in developing mice. Physiol. Behav. 94(4), 569-579 (2008).
38. Scalfi L, D'Arrigo E, Carandente V, Coltorti A, Contaldo F. The acute effect of dexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebocontrolled study. Int. J. Obes. Relat. Metab. Disord. 17(2), 91-96 (1993).
39. Van Gaal LF, Vansant GA, Steijaert MC, De Leeuw I. Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. Metabolism 44(2 Suppl. 2), 42-45 (1995).
40. Lafreniere F, Lambert J, Rasio E, Serri O. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study. Int. J. Obes. Relat. Metab. Disord. 17(1), 25-30 (1993).
41. Kogon MM, Krauchi K, van der Velde V, Van der Werf H, Keller U. Psychological and metabolic effects of dietary carbohydrates and dexfenfluramine during a low-energy diet in obese women. Am. J. Clin. Nutr. 60(4), 488-493 (1994).
42. Doucet E, St Pierre S, Almeras N, Mauriege P, Richard D, Tremblay A. Changes in energy expenditure and substrate oxidation resulting from weight loss in obese men and women: is there an important contribution of leptin? J. Clin. Endocrinol. Metab. 85(4), 1550-1556 (2000).
43. Levitsky DA, Troiano R. Metabolic consequences of fenfluramine for the control of body weight. Am. J. Clin. Nutr. 55(1 Suppl), S167- S172 (1992).
44. Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 67(1), 27-55 (2007).
45. Recasens MA, Barenys M, Sola R, Blanch S, Masana L, Salas-Salvado J. Effect of dexfenfluramine on energy expenditure in obese patients on a very-low-calorie-diet. Int. J. Obes. Relat. Metab. Disord. 19(3), 162-168 (1995).
46. Wacker DA, Miller KJ. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases. Curr. Opin. Drug Discov. Devel. 11(4), 438-445 (2008).
47. Miller KJ. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. Mol. Interv. 5(5), 282-291 (2005).
48. Thomsen WJ, Grottick AJ, Menzaghi F et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 325(2), 577-587 (2008).
49. Smith SR, Prosser W, Donahue D, Anderson C, Shanahan W. APD356-004 study group. Lorcaserin (APD356), a selective 5-HT2C agonist, safely induces weight loss in a 12-week study of healthy obese patients. Presented at: American Diabetes Association 66th Annual Scientific Sessions. Washington DC USA, 6 December 2006. •• Sentinel Phase II trial in the development of lorcaserin.
50. Sugden K, Tichopad A, Khan N, Craig IW, D'Souza UM. Genes within the serotonergic system are differentially expressed in human brain. BMC Neurosci. 10, 50 (2009).
51. Kaumann AJ, Levy FO. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol. Ther. 111(3), 674-706 (2006).
52. Xu J, Jian B, Chu R, Lu Z et al. Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am. J. Pathol. 161(6), 2209-2218 (2002).
53. Ross EM, Roberts WC. The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am. J. Med. 79(3), 339-354 (1985).
54. Moss N, Choi Y, Cogan D et al. A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties. Bioorg. Med. Chem. Lett. 19(8), 2206-2210 (2009).
55. Shyu KG. Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure? Circ. Res. 104(1), 1-3 (2009).
56. Xu Y, Jones JE, Kohno D et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 60(4), 582-589 (2008).
57. Lam DD, Przydzial MJ, Ridley SH, Yeo GS, Rochford JJ, O'Rahilly S, Heisler LK. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 149(3), 1323-1328 (2008).
58. Morgan M, Chen W, Anderson C, Prosser W, Donahue D, Shanahan W. Pharmacokinetic properties, metabolism, and tolerability of lorcaserin in health volunteers. Presented at: Annual Meeting of The Obesity Society. Phoenix, AZ, USA, 3-7 October 2008.
59. Munro JF, Seaton DA, Duncan LJ. Treatment of refractory obesity with fenfluramine. Br. Med. J. 2(5514), 624-625 (1966).
60. Stahl KA, Imperiale TF. An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity. Arch. Fam. Med. 2(10), 1033-1038 (1993).
61. Salmela PI, Sotaniemi EA, Viikari J, Solakivi-Jaakkola T, Jarvensivu P. Fenfluramine therapy in non-insulin-dependent diabetic patients: effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism. Diabetes Care 4(5), 535-540 (1981).
62. Hudson KD. The anorectic and hypotensive effect of fenfluramine in obesity. JR. Coll. Gen. Pract. 27(181), 497-501 (1977).
63. O'Connor HT, Richman RM, Steinbeck KS, Caterson ID. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. Int. J. Obes. Relat. Metab. Disord. 19(3), 181-189 (1995).
64. Turner P. Dexfenfluramine. Its place in weight control. Drugs 39(Suppl. 3), 53-62 (1990).
65. Carvajal A, García del Pozo J, Martín de Diego I, Rueda de Castro AM, Velasco A. Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis. Methods Find. Exp. Clin. Pharmacol. 22(5), 285-290 (2000).
66. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch. Intern. Med. 144(6), 1143-1148 (1984).
67. Weintraub M, Sundaresan PR, Schuster B et al. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin. Pharmacol. Ther. 51(5), 595-601 (1992).
68. Weintraub M, Sundaresan PR, Schuster B, Moscucci M, Stein EC. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. Clin. Pharmacol. Ther. 51(5), 602-607 (1992).
69. Weintraub M, Sundaresan PR, Schuster B et al. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase. Clin. Pharmacol. Ther. 51(5), 608-614 (1992).
70. Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Byrne L. Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication. Clin. Pharmacol. Ther. 51(5), 615-618 (1992).
71. Weintraub M, Sundaresan PR, Schuster B. Long-term weight control study. VII (weeks 0 to 210). Serum lipid changes. Clin. Pharmacol. Ther. 51(5), 634-641 (1992).
72. Weintraub M. Long-term weight control study: conclusions. Clin. Pharmacol. Ther. 51(5), 642-646 (1992).
73. 1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J. Med. Chem. 51(2), 305-313 (2008).
74. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17), 2735-2752 (2005).
75. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am. J. Clin. Nutr. 56(2), 320-328 (1992).
76. Aubin D, Gagnon A, Grunder L, Dent R, Allen M, Sorisky A. Adipogenic and antiapoptotic protein levels in human adipose stromal cells after weight loss. Obes. Res. 12(8), 1231-1234 (2004).
77. Liese AD, Mayer-Davis EJ, Tyroler HA et al. Development of the multiple metabolic syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Atherosclerosis risk in communities. Ann. Epidemiol. 7(6), 407-416 (1997).
78. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am. J. Clin. Nutr. 79(3), 379-384 (2004).
79. Zhu S, Heshka S, Wang Z, Shen W, Allison DB, Ross R, Heymsfield SB. Combination of BMI and waist circumference for identifying cardiovascular risk factors in whites. Obes. Res. 12(4), 633-645 (2004).
80. Blackburn GL, Waltman BA. Pharmacotherapy to reduce visceral fat. Clin. Cornerstone 7(2-3), 52-60 (2005).
81. Bays H, Dujovne CA. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr. Atheroscler. Rep. 8(2), 144-156 (2006).
82. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89(6), 2595-2600 (2004).
83. Swinburn BA, Carmichael HE, Wilson MR. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. Int. J. Obes. Relat. Metab. Disord. 20(11), 1033-1040 (1996).
84. Greco AV, Mingrone G, Capristo E, De, Gaetano A., Ghirlanda G, Castagneto M. Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with Type 2 diabetes mellitus. Metabolism 44(2 Suppl. 2), 57-61 (1995).
85. Ditschuneit HH, Flechtner-Mors M, Dolderer M, Fulda U, Ditschuneit H. Endocrine and metabolic effects of dexfenfluramine in patients with android obesity. Horm. Metab. Res. 25(11), 573-578 (1993).
86. Miner JL. The adipocyte as an endocrine cell. J. Anim. Sci. 82(3), 935-941 (2004).
87. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89(6), 2548-2556 (2004).
88. Ahima RS. Adipose tissue as an endocrine organ. Obesity.(Silver Spring) 14(Suppl. 5) S242-S249 (2006).
89. Caspar-Bauguil S, Cousin B, Galinier A et al. Adipose tissues as an ancestral immune organ: site-specific change in obesity. FEBS Lett. 579(17), 3487-3492 (2005).
90. Schaffler A, Muller-Ladner U, Scholmerich J, Buchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr. Rev. 27(5), 449-467 (2006). •• Excellent review of the pathogenic potential of adipose tissue, as it relates to inflammation.
91. Connor TJ, Kelly JP. Fenfluramine-induced immunosuppression: an in vivo analysis. Eur. J. Pharmacol. 455(2-3), 175-185 (2002).
92. Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin. Drug Saf. 8(3), 317-329 (2009).
93. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337(9), 581-588 (1997). • Publication that significantly contributed to the discussion regarding the potential association between fenfluramine/ dexfluramine and valvulopathy, which was followed by the withdrawal of these previously approved anti-obesity agents from the market.
94. Centers for Disease Control and Prevention (CDC). Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb. Mortal Wkly Rep. 46, 1061-1066 (1997).
95. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337(24), 1783 (2009).
96. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine- derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am. Heart J. 144(6), 1065-1073 (2002).
97. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N. Engl. J. Med. 339(11), 725-732 (1998).
98. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 101(17), 2071-2077 (2000).
99. Ryan DH, Bray GA, Helmcke F et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes. Res. 7(4), 313-322 (1999).
100. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 283(13), 1703-1709 (2000).
101. Gardin JM, Constantine G, Davis K, Leung C, Reid CL. Aortic valvular regurgitation: prevalence and clinical characteristics in a predominantly obese adult population not taking anorexigens. Echocardiography 23(7), 569-576 (2006).
102. Smith SA, Waggoner AD, Fuentes LD, vila-Roman VG. Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography. J. Am. Soc. Echocardiogr. 22(8), 883-889 (2009).
103. Fitzgerald LW, Burn TC, Brown BS et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57(1), 75-81 (2000).
104. Rothman RB, Baumann MH, Savage JE et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102(23), 2836-2841 (2000).
105. Mekontso-Dessap A, Brouri F et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113(1), 81-89 (2005).
106. Roth BL. Drugs and valvular heart disease. N. Engl. J. Med. 356(1), 6-9 (2007).
107. Bays H. Adiposopathy - defining, diagnosing, and establishing indications to treat 'sick fat': what are the regulatory considerations? US Endocrine Disease 2, 12-14 (2006).
108. Flum DR, Belle SH, King WC et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N. Engl. J. Med. 361(5), 445-454 (2009).
109. Krude H, Biebermann H, Schnabel D et al. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J. Clin. Endocrinol. Metab. 88(10), 4633-4640 (2003).
110. Obregon MJ. Thyroid hormone and adipocyte differentiation. Thyroid 18(2), 185-195 (2008).
111. Levacher C, Sztalryd C, Kinebanyan MF, Picon L. Effects of thyroid hormones on adipose tissue development in Sherman and Zucker rats. Am. J. Physiol. 246(1 Pt 1), C50-C56 (1984).
112. Bays H. The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy. Drugs RD 7(5), 289-302 (2006).
113. Nogueiras R, Wiedmer P, Perez-Tilve D et al. The central melanocortin system directly controls peripheral lipid metabolism. J. Clin. Invest. 117(11), 3475-3488 (2007).
114. Raposinho PD, White RB, Aubert ML The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat. J. Neuroendocrinol. 15(2), 173-181 (2003).
115. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J. 19(6), 1290-1300 (2000).
116. Bradley RL, Mansfield JP, Maratos-Flier E, Cheatham B. Melanin-concentrating hormone activates signaling pathways in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 283(3), E584-E592 (2002).
117. Digby JE, Chen J, Tang JY, Lehnert H, Matthews RN, Randeva HS. Orexin receptor expression in human adipose tissue: effects of orexin-A and orexin-B. J. Endocrinol. 191(1), 129-136 (2006).
118. Centers for Disease Control and Prevention. Overweight and Obesity http://cdc.gov/obesity/index.html (Accessed 20 July 2009).
119. World Health Organization. Global Strategy on Diet, Physical Activity and Health www.who.int/dietphysicalactivity/ publications/facts/obesity/en/ (Accessed 19 November 2009)
120. Precription Medications for the Treatment of Obesity. US Department of Health and Human Resources.National Institutes of Health. http://win.niddk.nih. gov/publications/ PDFs/prescriptionmeds1104bw.pdf (Accessed 9 September 2009)
121. Yu B, Nichols CD. Serotonin 5-HT2A receptor activity mediates adipocyte differentiation. The Journal of the Federation of American Societies for Experimental Biology. www.fasebj.org/cgi/content/meeting-abstract/23/1- MeetingAbstracts/941.5 (Accessed 8 August 2009).